The VICC.ORG Investigator Directory

Igor Puzanov, M.D.

Associate Professor of Medicine (Hematology/Oncology)
VICC Member
Medical Oncologist

Patient Contact Information:

Appointments: 615-936-8422
Further Information: 877-936-8422

Henry-Joyce Cancer Clinic
1301 Medical Center Drive, Suite 1710
Nashville, Tennessee 37232-7415
Phone: 615-936-8422 or 1-877-936-8422
Fax: 615-343-8668

Healthcare Provider Contact Information:

2220 Pierce Avenue
777 Preston Research Building
Nashville, TN 37232-6307


Dr. Puzanov is an Assistant Professor of Medicine in the Division of Hematology-Oncology.  Dr. Puzanov joined our faculty in July of 2005 after completing a three-year fellowship in Hematology-Oncology at Vanderbilt University Medical Center.  He completed his residency in Internal Medicine at University of Texas Southwestern Medical Center at Dallas and was board certified in 2001. Prior to that, he received his M.D. degree from Charles University in Prague. Dr. Puzanov has been a member of the Phase I team at Vanderbilt as a fellow and as a faculty member.  He led the Phase I team as its Interim Director since December 2008 and was appointed Associate Director of the Phase I Program in September 2009.  In his new role, he is responsible for working closely with the Director, Dr. Jordan Berlin, on the overall scientific and administrative leadership of a Phase I team.  The main focus of his efforts will be to develop investigator initiated trials (IITs) using the preclinical data generated from the VICC research programs.

Dr. Puzanov completed the ASCO/AACR Methods in Clinical Cancer Research Workshop in 2004 and received his Masters of Science in Clinical Investigation degree from Vanderbilt in May, 2007. He has been the PI of six Phase I and four Phase I/II studies including PI on a Phase I IIT of SJG-136, sponsored by CTEP and a TRI contract to Dr. Puzanov for correlative studies. He is a member of the GU Core Committee for ECOG and was a co-investigator on a Phase I/II IIT PHI0470 sponsored by CTEP/NCI analyzing the use of bevacizumab/sorafenib in renal cell carcinoma. This regimen has been taken forward into an ECOG-sponsored, multi-arm Phase II trial of combination regimens E2804 (The BeST trial). Collaboration with the cardiology department led to the recent submission of a grant to study cardiotoxicity of anti-VEGF therapies for cancer (PI: Daniel Lenihan, MD).

Dr. Puzanov’s additional responsibilities include conceptualization of LOIs, integration of appropriate correlative studies, development and activation of IITs, management of patients and assessment of toxicities, and analysis and presentation of Phase I and Phase I/II studies.


Clinical Interest:

Development of novel therapies for patients with solid tumors including melanoma and renal cell carcinoma



  • Charles University, Prague, Czechoslovakia, M.D., 1991
  • Internship, Internal Medicine and Surgery, Faculty Hospital Royal Vineyards,
  • Residency/Internship, Internal Medicine, UT Southwestern Medical Center
  • Fellowship in Medical Oncology and Hematology, Vanderbilt University
  • Master of Science in Clinical Investigation, Vanderbilt University

You do not have JavaScript enabled. This site works better with JavaScript turned on.